David Hay

David Hay

All edits

Edits on 29 Sep, 2020
Carla Faraguna
Carla Faraguna edited on 29 Sep, 2020
Edits made to:
Topic thumbnail

Prof David Hay David Hay

Edits on 30 Oct, 2019
Golden AI
Golden AI edited on 30 Oct, 2019
Edits made to:
Infobox (+1/-1 properties)
Infobox
Founder of
Founder of
HigherSteaks
Edits on 23 Jan, 2019
Golden AI
Golden AI edited on 23 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Person
Edits on 22 Jan, 2019
Golden AI
Golden AI edited on 22 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Founder of
Edits on 29 Nov, 2018
Carla Faraguna
Carla Faraguna edited on 29 Nov, 2018
Edits made to:
Article (+21/-21 characters)
Article

Prof. David Hay is the chair of Tissue Engineering and group leader at MRC Centre for Regenerative Medicine at the University of Edinburgh. He has a long-standing international reputation in induced pluripotent stem cellpluripotent stem cell biology and hepatocyte differentiation, evidenced by over 90 publications and over 3500 citations. His research goals include the translation of stem cell-derived hepatocytes into scalable manufacturing processes. Prof. David Hay is also a co-founder of Stemnovate, a company awarded with an Innovate grant to develop innovative platforms for drug screening using cell biology, and FibromEd, a company focused on reducing human drug attrition through the creation of novel predictive human liver models. He holds a number of patents (including 'Polymers for Growing Cells' and 'Polymers for Growing Endothelial Cells') and has over 15 years of experience working with pluripotent stem cells. He has worked on fascinating problems including the production of 3D culture systems, semi-automated induced pluripotent stem cell-based screening platforms and the development of renewable sources of liver tissue.

Edits on 17 Nov, 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Nov, 2018
Edits made to:
Infobox (-1 properties)
Article (+18/-18 characters)
Article

Prof. David Hay is the chair of Tissue EngineeringTissue Engineering and group leader at MRC Centre for Regenerative Medicine at the University of Edinburgh. He has a long-standing international reputation in induced pluripotent stem cell biology and hepatocyte differentiation, evidenced by over 90 publications and over 3500 citations. His research goals include the translation of stem cell-derived hepatocytes into scalable manufacturing processes. Prof. David Hay is also a co-founder of Stemnovate, a company awarded with an Innovate grant to develop innovative platforms for drug screening using cell biology, and FibromEd, a company focused on reducing human drug attrition through the creation of novel predictive human liver models. He holds a number of patents (including 'Polymers for Growing Cells' and 'Polymers for Growing Endothelial Cells') and has over 15 years of experience working with pluripotent stem cells. He has worked on fascinating problems including the production of 3D culture systems, semi-automated induced pluripotent stem cell-based screening platforms and the development of renewable sources of liver tissue.

Edits on 31 Oct, 2018
Benjamina Bollag
Benjamina Bollag edited on 31 Oct, 2018
Edits made to:
Topic thumbnail

David Hay

Benjamina Bollag
Benjamina Bollag edited on 31 Oct, 2018
Edits made to:
Description (-17 characters)
Topic thumbnail

David Hay

<p>Clean meat</p>

Benjamina Bollag
Benjamina Bollag edited on 31 Oct, 2018
Edits made to:
Infobox (+1 properties)
Description (+17 characters)
Article (+1127 characters)
Further reading (+2 rows) (+4 cells) (+138 characters)
Companies (+2 rows) (+6 cells) (+76 characters)
Related Topics (+4 topics)

David Hay

<p>Clean meat</p>

Article

Prof. David Hay is the chair of Tissue Engineering and group leader at MRC Centre for Regenerative Medicine at the University of Edinburgh. He has a long-standing international reputation in induced pluripotent stem cell biology and hepatocyte differentiation, evidenced by over 90 publications and over 3500 citations. His research goals include the translation of stem cell-derived hepatocytes into scalable manufacturing processes. Prof. David Hay is also a co-founder of Stemnovate, a company awarded with an Innovate grant to develop innovative platforms for drug screening using cell biology, and FibromEd, a company focused on reducing human drug attrition through the creation of novel predictive human liver models. He holds a number of patents (including 'Polymers for Growing Cells' and 'Polymers for Growing Endothelial Cells') and has over 15 years of experience working with pluripotent stem cells. He has worked on fascinating problems including the production of 3D culture systems, semi-automated induced pluripotent stem cell-based screening platforms and the development of renewable sources of liver tissue.

Companies

Company
CEO
Location
Products/Services

Higher Steaks

Benjamina Bollag

London / Bristol

Stemnovate

Ruchi Sharma

Cambridge

Further reading

Title
Author
Link
Type

David Hay | MRC Centre for Regenerative Medicine

Web

Infobox
Related Topics
Benjamina Bollag"Initial topic creation"
Benjamina Bollag created this topic on 31 Oct, 2018
Edits made to:
Topic thumbnail

 Prof David Hay

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.